E xpansion of the myocardial interstitial space is a feature common to a range of cardiac pathologies and seems fundamental to the process of adverse left ventricular (LV) remodeling. [1] [2] [3] [4] Interstitial expansion, in part attributable to accumulation of collagen, is associated with changes in mechanical and electric properties of the myocardium and as such may represent a sentinel phenotype, transitional between healthy myocardium and diseased myocardium associated with increased mortality risk. [5] [6] [7] [8] [9] Furthermore, interstitial expansion is reversible and a potential therapeutic target. 10-12 Quantification of the myocardial interstitial space, or extracellular volume (ECV), may therefore represent an important diagnostic and prognostic biomarker.
Endomyocardial biopsy represents the current gold standard for assessment of the myocardial interstitium; however, its invasive nature and lack of whole heart coverage restrict its clinical use for this purpose. Cardiovascular magnetic resonance (CMR) techniques that potentially allow noninvasive evaluation of the interstitial space have generated considerable recent interest.
Gadolinium chelates are standard extracellular contrast agents that potently shorten T 1 relaxation time. Gadolinium concentration is directly related to change in the relaxation rate R 1 (where R 1 is the reciprocal of T 1 ). Therefore, T 1 measurement (mapping) before and after contrast administration can be used to calculate gadolinium concentration in myocardium and blood. At contrast agent equilibrium, gadolinium concentration is equal in blood and myocardium, and because the volume of distribution of gadolinium (or ECV) in blood is known from the hematocrit, myocardial ECV can be calculated.
This approach requires a steady state to exist between blood and myocardial contrast agent for the effect of contrast agent kinetics to be removed. Using a primed gadolinium infusion to achieve contrast agent equilibrium (equilibrium contrast CMR), Flett et al 13 demonstrated a strong correlation between CMR measurement of myocardial ECV and histological collagen volume fraction. However, because of the potentially cumbersome nature of this technique, 2 alternative methods of assessing ECV have become more widely adopted.
The first, which involves a contrast agent bolus (ie, without a subsequent infusion), assumes contrast agent kinetic effects to be negligible because of a dynamic equilibrium between blood and myocardium (dynamic-equilibrium CMR [DynEq-CMR]). 9, [14] [15] [16] [17] [18] [19] In the second method, an isolated myocardial T 1 measurement is made at a fixed time point after a bolus of contrast agent (ie, without precontrast or blood T 1 measurements) and is used as a surrogate measure of ECV (isolated-T 1 ). [20] [21] [22] [23] However, despite these techniques being applied to a rapidly expanding number of pathologies, both have potential shortcomings; the assumed dynamic equilibrium proposed in the first method may not always hold true in reality, and the second technique may be confounded by factors, such as body fat percentage, renal function, and hematocrit. Systematic in vivo histological validation of these techniques in humans is lacking. [24] [25] [26] The aims of the current study were to first provide comprehensive, whole-heart, histological validation of the DynEq-CMR technique for measurement of myocardial ECV. This, at the same time, allowed assessment of the validity of isolated-T 1 technique. Second, we aimed to assess the effect of contrast agent dose, postcontrast acquisition time, myocardial regionality, cardiac cycle, and sex on DynEq-CMR ECV measurement.
Methods

Study Design
All research was performed at University Hospital of South Manchester National Health Service (NHS) Trust, United Kingdom. An ethics committee of the UK National Research Ethics Service approved the study, and written informed consent was obtained from all participants. The work was conducted according to the Helsinki Declaration.
The study comprises 3 parts: (1) phantom studies; performed to validate the accuracy of the T 1 mapping sequence used and to calculate a T 1 heart-rate correction algorithm (see the online-only Data Supplement); (2) histological validation. CMR was performed prospectively in patients awaiting heart transplantation. When these patients subsequently underwent transplantation, the explanted hearts were used to provide whole-heart histological validation of the DynEq-CMR and isolated-T 1 techniques; and (3) the effect of contrast dose, postcontrast acquisition time, myocardial regionality, cardiac cycle, and sex on DynEq-CMR was assessed in healthy volunteers.
CMR Imaging
All CMR imaging was performed with the same 1.5 Tesla scanner (Magnetom Avanto, Siemens Healthcare Sector, Erlangen, Germany) equipped with a 32-element phased-array coil.
T 1 measurements were made using an ECG-gated single-shot modified Look-Locker inversion recovery (MOLLI) sequence as described by Messroghli et al. 27 Typical parameters were field of view 340×255 mm, matrix 192×138, 8-mm slice thickness, flip angle 35°, parallel imaging factor 2 with 24 reference lines, 6/8 partial Fourier k-space sampling, acquisition time 201 ms for a single image, and initial effective inversion time (TIeff) 100 ms with a TIeff increment of 80 ms. To sample T 1 recovery, serial single-shot diastolic images were acquired every heart beat after 3 nonselective adiabatic inversion pulses (ie, 3, 3, and 5 images after each inversion pulse, totaling 11 images), with 3 dummy heart beats before the second and third inversion pulses to allow recovery (17 heart beat total acquisition duration).
The gadolinium contrast agent used throughout the study was gadopentetate dimeglumine (Gd-DTPA; Magnevist; Bayer Healthcare, Leverkusen, Germany), administered as a single bolus of 2 mL/s followed by a 30-mL saline chaser bolus delivered at the same flow rate using a power injector.
Histological Validation
All patients on the heart transplant waiting list at University Hospital of South Manchester NHS Trust, United Kingdom (1 of 6 UK adult heart transplant centers), between January 1, 2011 and July 1, 2012, were screened for study eligibility. Of the 54 patients on the waiting list during this period, 41 had an intracardiac device that prohibited CMR, and 2 of the 13 patients without devices were deemed too unwell for CMR by the supervising medical team. Eleven patients were, therefore, invited for CMR, of which 2 refused consent. The 9 remaining patients underwent CMR, of which 6 underwent heart transplantation. As prespecified, no patients with acute myocardial inflammation (known or suspected myocarditis, acute myocardial infarction) or cardiac amyloidosis were included.
The CMR protocol included LV short-axis MOLLI sequence acquisition at basal, mid, and apical ventricular levels before, and 10 and 15 minutes after a bolus of 0.20 mmol/kg Gd-DTPA contrast agent ( Figure 1 ). Standard long-and short-axis steady-state-free precession cine imaging was performed to assess LV mass and volumetric parameters. Standard late gadolinium enhancement (LGE) imaging was performed ≥10 minutes after contrast agent administration using spoiled gradient echo segmented inversion recovery, and phasesensitive inversion recovery segmented gradient echo, sequences. 28 Blood samples were taken at the time of CMR to measure hematocrit.
At the time of transplantation, the explanted hearts were immediately fixed in 10% buffered formalin. The hearts were cut at basal, mid, and apical LV levels (using the MOLLI slice positions as guidance; Figure 1 ), and 16 tissue blocks were taken from the LV of each heart (96 samples in total) according to the American Heart Association/ American College of Cardiology 16-segment model 29 before being embedded in paraffin and stained with picrosirius red. High-power magnification (×200) digital images, excluding perivascular areas, underwent automated image analysis (macro written in ImageJ Bethesda, MD). 30 As described previously, 13 a combination of SD from mean signal and isodata automatic thresholding derived the collagen area, expressed as a percentage of total myocardial area, excluding fixation artifact. Twelve high-power fields were assessed per segment (1152 high-power fields were assessed in total), and mean histological collagen volume fraction (CVF, %) and CVF heterogeneity (coefficient of variation between fields) were obtained. To determine whether CVF measurements were affected by the degree of magnification used to acquire the histological images, CVF measurements were repeated at 2 additional magnifications (×50 and ×100) in 2 randomly selected tissue blocks from each patient (12 samples [13%] in total, ie, an additional 288 histological images).
Effect of Contrast Agent Dose, Acquisition Time, Myocardial Regionality, Cardiac Cycle, and Sex
Thirty completely asymptomatic healthy volunteers, with no known risk factors or history of cardiac disease, normal physical examination, and normal ECG, underwent CMR (subjects were not patients who had been referred for CMR that was subsequently found to be normal). CMR (cine and LGE imaging) was normal in all cases.
Volunteers were prospectively split into 3 age-and sex-matched groups and received Gd-DTPA contrast agent at the following doses: group A, 0.10 mmol/kg; group B, 0.15 mmol/kg; and group C, 0.20 mmol/kg.
The CMR protocol included a MOLLI sequence acquisition in shortaxis at midventricular level before and at 2-, 4-, 6-, 8-, 10-, 12-, 14-, 15-, 16-, 18-, and 20-minute postcontrast administration. In addition, MOLLI imaging was also performed in early systole (150 ms after the R wave) precontrast and at 10-and 15-minute postcontrast administration. Standard long-and short-axis steady-state-free precession cine imaging was performed to assess LV mass and volumetric parameters.
LGE imaging of the entire heart in short-axis was performed using single-shot phase sensitive inversion recovery imaging. 31 Blood samples were taken at the time of CMR to measure the hematocrit.
CMR Image Analysis
For T 1 relaxation time measurements, endocardial and epicardial contours were drawn on the MOLLI images using Osirix Imaging Software (Pixmeo; Switzerland; version 4.0). An additional region of interest was drawn in the blood pool, avoiding papillary muscles and trabeculae, and the anterior right ventricular septal insertion point was marked. Regions of interest were manually translated on each TIeff time image to allow motion compensation. The same regions of interest were used on corresponding pre-and postcontrast images. To obtain voxel-wise T 1 relaxation times, a 3-parameter fit to the signal intensity, S as a function of TIeff, was performed according to S(TIeff)=A−Be (-TIeff/T1*) and T 1 was calculated as T 1 =T 1 *((B/A)−1). Fitting was performed using MatLab (MathWorks, Natick, MA; vR2009a). Using the anterior septal insertion point as reference, T 1 maps were segmented according to the American Heart Association/ American College of Cardiology model. 29 Mean voxel T 1 relaxation time in each segment before and after contrast was then used to calculate segmental myocardial ECV according the following formula:
where the partition coefficient, λ=ΔR 1 (myocardium)/ΔR 1 (blood). ΔR 1 is proportional to contrast agent concentration.
Separate ECV calculations were performed using the 10-and 15-minute postcontrast T 1 values acquired in patients awaiting transplantation, and using the 2-to 20-minute postcontrast T 1 values acquired in healthy subjects.
Precontrast and 15-minute postcontrast MOLLI image analysis was independently repeated in 50% (3 patients, 48 segments) of patients who had CMR before undergoing transplantation, and 33% of the healthy subjects (10 patients, 60 segments) by a second observer to assess interobserver variability of ECV measurement. Patients were randomly selected.
LV mass, end-diastolic volume, end-systolic volume, and ejection fraction were quantified from steady-state-free precession images using CMRtools (Cardiovascular Imaging Solutions, London, United Kingdom). LGE images were reported visually by 2 experienced operators (C.A.M. and M.S.). Segments were recorded as containing no LGE, infarct-typical LGE, or infarct-atypical LGE.
Statistical Analysis
All data were analyzed in a blinded fashion, with independent analysis of CMR (C.A.M. and M.S.) and histology (P.B.) data. Statistical analysis was performed using SPSS (IBM, version 19, IBM, Armonk, NY). Continuous variables are expressed as mean±SD. For the histological validation, regression analysis using generalized estimating equations (GEEs) to adjust for repeated measurements within each subject was used to assess the relationship between DynEq-CMR-derived ECV and histological CVF. Within-subject and between-subject correlations were calculated using the methods described by Bland et al. 32, 33 The same analyses were used to assess the relationship between isolated postcontrast T 1 measurements and histological CVF. As prespecified, analyses were repeated after excluding segments containing infarct-typical LGE and after excluding segments containing any LGE (infarct-typical or infarctatypical). Characteristics of healthy volunteers were compared across the 3 groups using 1-way ANOVA, as were precontrast T 1 measurements. The effect of contrast agent dose on repeated postcontrast T 1 measurements and the effect of contrast agent dose, myocardial region, and sex on repeated ECV measurements were assessed using a repeated measures ANOVA model. To assess the change in ECV measurement over time, ECV values calculated at 2 and 20 minutes post contrast were compared within each contrast agent dose group using a paired t test. Diastolic and systolic ECV measurements were compared within each contrast dose group using a paired t test. Interobserver agreement was evaluated using the repeatability coefficient, 34 which calculates the range within which measurements by 2 different observers are expected to lie for 95% of subjects, and intraclass correlation coefficient (ICC).
Results
Histological Validation
Characteristics of each of the 6 patients who received a heart transplant after CMR are summarized in Table 1 . Median time between CMR and transplantation was 29 days (in 5 patients the interval was ≤40 days, but in 1 patient the interval was 276 days). Mean histological CVF was 21.6±12.4% (range, 3.3%-55.2%; Figure 2 ). Mean DynEq-CMR-derived ECV calculated using the 10-minute postcontrast T 1 values was 43.8±7.0% (range, 31.1%-65.1%; median within-subject range, 20.2%), and using the 15-minute postcontrast T 1 values was 43.9±6.7% (range, 30.9%-68.4%; median within-subject range, 18.2%).
There was a significant linear relationship between ECV measured by DynEq-CMR, using both the 10-or 15-minute postcontrast T 1 values and the histological CVF (P<0.001 for both using GEE; Figure 3 ). Although high for both, the correlation was marginally higher when ECV was calculated using the 15-minute postcontrast T 1 values (withinsubject: r=0.745; P<0.001; r 2 =0.555 and between-subject: r=0.945; P<0.01; r 2 =0.893) compared with when the 10-minute postcontrast values were used (within-subject: r=0.728; P<0.001; r 2 =0.530 and between-subject: r=0.880; P<0.01; r 2 =0.774). The linear regression equation for the relationship between DynEq-CMR-derived ECV using the 15-minute postcontrast T 1 values and histological CVF was histological CVF=1.45×ECV-42. The correlation between mean ECV and CVF on a per individual basis was r=0.945; P=0.004; and r 2 =0.893 ( Figure 4 ).
There was a significant linear relationship between isolated postcontrast T 1 measurements made at 10 and 15 minutes post contrast and histological CVF (P<0.001 for both using GEE; Figure 3 ); however, this was largely driven by the within-subject correlations (isolated 10-minute postcontrast T 1 : r=−0.690; P<0.001; r 2 =0.475 and isolated 15-minute postcontrast T 1 : r=−0.741; P<0.001; r 2 =0.550). The betweensubject correlations were not significant (isolated 10-minute postcontrast T 1 : r=−0.028; P=0.96 and isolated 15-minute postcontrast T 1 : r=−0.207; P=0.69). There was no correlation between precontrast T 1 values and histological CVF (P=0.437 using GEE; within-subject: r=0.138; P=0.192 and betweensubject: r=0.199; P=0.71).
In light of these findings, all subsequent analyses were performed using ECV calculated with DynEq-CMR using the 15-minute postcontrast T 1 values.
There was a significant linear relationship between ECV and histological CVF in septal and nonseptal segments (P<0.001 using GEE for both), with minimal difference in within-subject and between-subject correlations (septum: within-subject, r=0.750; P<0.001; r 2 =0.560 and between-subject, r=0.940; P<0.01; r 2 =0.884; and nonseptum: within-subject, r=0.722; P<0.001; r 2 =0.521 and between-subject, r=0.941; P<0.01; r 2 =0.885). The significant linear relationship between ECV and histological CVF was also maintained across ventricular levels (P<0.001 using GEE for both basal and midventricular segments, and apical segments), with minimal difference in within-subject and between-subject correlations (basal and mid ventricle: within-subject, r=0.727; P<0.001; r 2 =0.529 and between-subject, r=0.960; P<0.01; r 2 =0.922; and apical ventricle: within-subject, r=0.748; P<0.001; r 2 =0.559 and between-subject, r=0.892; P<0.01; r 2 =0.796).
Infarct-typical
LGE was present in 32 segments and infarct-atypical LGE was present in a further 10 segments. Only 1 segment displayed LGE throughout its entirety. When segments containing infarct-typical LGE were excluded (analysis performed on 64 segments), the linear relationship between ECV and histological CVF was maintained (P<0.001 using GEE; within-subject: r=0.682; P<0.001; r 2 =0.465 and between-subject: r=0.912; P<0.01; r 2 =0.832; Figure 5 ). Likewise, the linear relationship between ECV and histological CVF remained when segments containing any LGE (infarcttypical and infarct-atypical patterns) were excluded (analysis performed on 54 segments; P<0.001 using GEE; withinsubject: r=0.652; P<0.001; r 2 =0.426 and between-subject: r=0.843; P<0.02; r 2 =0.711; Figure 5 ).
Effect of Contrast Agent Dose, Myocardial Regionality, Cardiac Cycle, and Sex on ECV
There were no significant differences in subject characteristics between contrast agent-dose groups ( Table 2) .
Precontrast myocardial (group A, 1051±49 ms; group B, 1045±49 ms; and group C, 1040±43 ms; P=0.87) and blood (group A, 1678±98 ms; group B, 1645±118 ms; and group C, 1686±101 ms; P=0.66) T 1 relaxation times were not significantly different between groups. Mean myocardial (group A, 542±65 ms; group B, 465±69 ms; group C, 407±55 ms; P<0.001) and blood (group A, 407±73 ms; group B, 307±67 ms; and group C, 252±48 ms; P<0.001) T 1 relaxation times averaged over all time points post contrast shortened significantly as contrast dose increased ( Figure 6 ). Measurements of mean ECV averaged over all time points were significantly higher in group A compared with groups B and C (group A, 27.7±3.7%; group B, 25.8±3.4%; and group C, 25.8±2.8%; P<0.001), but the difference between groups B and C was not significant ( Figure 6 ). Mean measured ECV increased linearly over time in each group; between the 2-and the 20-minute postcontrast acquisitions measured ECV increased from 27.2±2.7% to 28.8±3.4% (P=0.020) in group A; 25.3±2.8% to 26.5±3.2% (P=0.004) in group B; and 25.2±1.7% to 26.2±2.1% (P=0.068) in group C.
ECV varied significantly between myocardial regions. In each group ECV was highest in the septum and lowest in the lateral wall, as exemplified by group C (results for other groups were similar): anterior 24 
Comparison of ECV in Health and Disease
In healthy subjects receiving 0.20 mmol/kg contrast agent (ie, group C), mean segmental ECV calculated using 15-minute postcontrast T 1 values was 25.5±2.6%. In patients before transplantation (who received the same type and dose of contrast agent), mean ECV, also calculated using 15-minute postcontrast T 1 values, in segments without LGE was 41.4±5.0% (P<0.001 when compared with healthy subjects), and in segments with LGE was 47.0±7.4% (P<0.001 when compared with healthy subjects and when compared with segments without LGE; Figure 7 ). In patients before transplantation, there was a significant difference in mean ECV between segments without LGE, segments with infarctatypical LGE (45.8±4.7%), and segments with infarct-typical LGE (47.4±8.1%; P<0.001). On post hoc analysis the difference in ECV between segments with infarct-typical LGE and segments without LGE was significant (P<0.001), but the difference between segments with infarct-atypical LGE and segments without LGE was not (P=0.125; Figure 7 ).
Mean precontrast myocardial T 1 relaxation time was significantly higher in patients before transplantation than in healthy subjects (1187±163 versus 1045±46 ms; P<0.001).
Repeatability
Interobserver variability for DynEq-CMR measurement of ECV in healthy subjects was 2.3% (ICC, 0.932), ranging ECV was significantly higher in segments without LGE in patients awaiting transplantation than in healthy subjects. ECV was significantly different between segments without LGE, segments with infarct-atypical LGE, and segments with infarct-typical LGE, but on post hoc analysis only the difference between segments with infarct-typical LGE and segments without LGE was significant (P<0.001). from 1.4% (ICC, 0.969) for septal segments to 2.7% (ICC, 0.914) for nonseptal segments. Interobserver variability for DynEq-CMR measurement of ECV in patients before transplantation was 5.1% (ICC, 0.883), ranging from 2.9% (ICC, 0.944) for septal segments to 5.9% (ICC, 0.850) for nonseptal segments, and ranging from 4.5% (ICC, 0.907) for basal and midventricular segments to 6.7% (ICC, 0.798) for apical segments. For histological CVF assessment, interobserver variability was 2.8% (ICC, 0.994); however, within the same tissue sample, CVF was not uniform between high-powered fields, with a mean SD of 49% normalized to CVF%. Mean CVF measurements did not vary significantly according to histological magnification (×200, 14.0±11.2%; ×50, 14.4±12.5%; ×100, 14.0±11.7%; P=0.507).
Discussion
This is the first human study to provide comprehensive histological validation of the DynEq-CMR technique for quantification of myocardial ECV, and the first to provide LV histological validation of the isolated postcontrast T 1 measurement technique. Indeed, this is the largest histological validation, in terms of number of tissue samples, of any CMR ECV quantification method, and the only to provide whole heart tissue corroboration.
The DynEq-CMR technique relies on the assumption of a 2-compartment model, whereby a steady state is assumed to exist between the intravascular and interstitial compartments, with equal contrast agent concentrations in each, because of rapid exchange of contrast agent between the compartments. The small increase in ECV over time seen here ( Figure 6 ), which is in keeping with the findings of Kawel et al 19 and Schelbert et al, 14 suggests that the 2-compartment model may be limited and an incomplete dynamic equilibrium between blood and myocardium is achieved. The lack of equilibrium may be because of penetration of gadolinium into other compartments, such as bone and synovial fluid, and because of faster renal clearance than exchange rate between compartments. Indeed, the latter reason, in particular, may explain the significantly higher ECV values and greatest increase in ECV over time, seen in the healthy subjects receiving the lowest contrast dose.
As a result of the incomplete dynamic equilibrium, the correlation between DynEq-CMR-derived ECV and histological CVF changed over time. Nevertheless, the relationship between DynEq-CMR-derived ECV and histological CVF in the current study is comparable with that found in the study by Flett et al 13 using the EQ-CMR technique (r 2 =0.80), in which basal septal ECV was compared with histological CVF of tissue obtained from the basal septum at surgical biopsy in patients undergoing valve replacement for aortic stenosis (18 patients) or myectomy for hypertrophic cardiomyopathy (8 patients). The DynEq-CMR technique used here, however, offers advantages compared with the EQ-CMR technique in terms of being substantially simpler to perform and less time consuming and could easily be incorporated into routine scanning protocols.
There was a strong linear relationship between CMRderived ECV and histological CVF across the whole spectrum of ECV and CVF, which is an important finding as it means that ECV is suitable for stratifying patients based on CVF. Nevertheless, the intercept of the linear regression equation for the relationship between ECV and CVF was not zero, and the slope was different from 1 (unity), findings which are in keeping with those of Flett et al 13 and Messroghli et al. 25 As discussed by Di Carli et al, 35 the y-intercept represents a surrogate for all of the multiple components of the myocardial interstitium, which as well as collagen include non-collagenous proteins, fibroblasts, endothelial cells, and vessels. In addition, although we excluded patients with specific myocardial inflammatory conditions per se, all subjects had end-stage heart failure and as such myocardial inflammation, and hence edematous expansion of the interstitial space without collagen deposition, may have been present, which may be one explanation for the higher mean precontrast T 1 seen in pretransplant patients compared with healthy volunteers. As such it is logical to assume that CMR-derived ECV does not only reflect CVF; however, it seems that excess ECV beyond the baseline is explained by increases in CVF, provided other causes of ECV expansion are excluded. The y-intercept and slope of the equation may also have been influenced by changes in the extracellular compartment relating to the tissue processing itself, and by the CVF quantification technique.
Flett et al 13 excluded patients who demonstrated any LGE in the region of the biopsy. Wong et al, 9 who demonstrated an association between DynEq-CMR-derived ECV and short-term all-cause mortality (but without histological corroboration), excluded regions of myocardium in the vicinity of infarct-typical LGE but included myocardium displaying infarct-atypical LGE. Others have quantified ECV in myocardium exhibiting infarct-typical LGE (also without histological corroboration). 16, 36 Expansion of the myocardial interstitial space seems to occur as a continuous spectrum. As such we included all tissue samples in our analysis, regardless of LGE status, and simply quantified ECV in each. Nevertheless, our study demonstrated that the correlation between DynEq-CMR-derived ECV and histological CVF remained strong when segments containing any LGE were excluded and when segments containing infarct-typical LGE only were excluded, as well as when segments containing LGE were included.
Indeed, this study serves to highlight the potential shortcomings of the LGE technique relating to its relative signal intensity nature. Although the LGE technique is very well established for infarction detection and quantification, the ability of LGE to detect and quantify myocardial fibrosis in nonischemic cardiomyopathies is much less well validated. Myocardial fibrosis exists as a spectrum from diffuse to focal. Such homogeneity, or lack of heterogeneity, is problematic for the LGE technique because it relies on normal regions of myocardium to serve as reference for nulling. As a result, LGE quantification (and hence quantification of fibrosis via the LGE technique) in nonischemic cardiomyopathies is dependent on the signal intensity threshold used. 37 As demonstrated in Figure 5 , in the current study, there was considerable overlap in histological CVF between segments that displayed LGE and those that did not (although it should be recognized that CVF and ECV values in the current study represent mean values for entire segments, with only 1 segment displaying LGE throughout). Furthermore, the difference in mean ECV between segments without LGE and those with atypical LGE was not significant, although overall mean differences in ECV may not be reflective of differences in individual patients. Nevertheless, in keeping with other work, this study suggests that myocardial fibrosis in nonischemic cardiomyopathies may be better assessed using ECV techniques rather than LGE. 38 The correlation between DynEq-CMR-derived ECV and histological CVF was maintained throughout the LV, although there was greater ECV measurement variability in nonseptal compared with septal regions and in apical compared with basal and midventricular myocardium, likely reflecting the comparatively thinner ventricular walls in these regions. The degree of variability in the midventricular slice was comparable with that reported in other studies 14, 16 ; variability at other ventricular levels has not previously been reported.
Mean DynEq-CMR-derived ECV in healthy subjects was in keeping with that found in other studies. 9, [14] [15] [16] 18, 19, 39 Interestingly, ECV was significantly higher in the septum compared with other myocardial regions in healthy subjects. This is in keeping with histological data from healthy myocardium, which demonstrate higher collagen content in the septum compared with other regions, 40 and with DynEq-CMR data reported by Kawel et al. 19 This finding, which may be secondary to the septum being exposed to mechanical strain from both ventricles, has important implications both in terms of CMR ECV measurement and histological assessment of CVF, as septal sampling seems not necessarily representative of other myocardial regions.
In addition, ECV was seen to vary significantly between sexes. This is in keeping with the findings of Sado et al 39 who, using EQ-CMR in healthy subjects with a similar age range to here, found sex was an independent predictor of ECV in multivariate analysis (myocardial mass, hematocrit, and patient height were not); indeed, the absolute difference in ECV between sexes reported by Sado et al 39 is very similar to that found here. The reasons for the sex difference are not clear. However, given that the correlation between ECV and histological CVF was maintained throughout the heart, with low observer variability particularly in the midventricular slice, this finding seems genuine (ie, it does not seem to be related to potentially greater partial voluming effects in theoretically thinner female LV walls). As Sado et al 39 discuss, it may be that this sex difference in ECV contributes to known differences in cardiovascular disease expression between men and women. Further investigation of this finding is required.
Mean DynEq-CMR-derived ECV in segments containing LGE was similar to that reported by Ugander et al, 16 who assessed ECV in patients with cardiac disease exhibiting infarct-typical or infarct-atypical LGE undergoing clinical CMR. However, mean ECV in myocardium remote from segments containing LGE in the pretransplant patients in the current study was substantially higher than ECV in myocardium remote from segments containing LGE in the study by Ugander et al. 16 This is likely to reflect the end-stage nature of cardiac disease in the cohort studied here. As a result, although there was considerable overlap between ECV in healthy subjects and ECV in myocardium in patients with cardiac disease but remote from LGE in the study by Ugander et al 16 (and in other studies), 9, 39 there was very little overlap in the current study.
Iles et al 24 found a significant correlation (r=−0.7; P=0.03) between LV midventricular isolated 15-minute postcontrast T 1 values and histological CVF in 9 heart transplant recipients, although tissue was of right ventricular origin and of small volume (obtained via transvenous endomyocardial biopsy), and this technique has been increasingly applied as a surrogate for ECV. However, isolated postcontrast T 1 measurements are confounded by several factors, such as renal function, hematocrit, body fat, and myocardial steatosis. In keeping with this, although the within-subject correlation between isolated postcontrast T 1 measurements and histological CVF was high in the current study, there was no significant correlation between subjects.
Limitations
Although the number of tissue samples included in this study is large, the total number of patients is relatively small. However, this reflects the difficulty in obtaining whole-heart histological data from patients who have recently undergone CMR, and who do not have an acute inflammatory myocardial condition. A greater number of patients could potentially have been recruited by performing the study using postmortem tissue obtained from patients who had undergone CMR for other reasons and subsequently died. However, immediate formalin fixation would not have been possible, which may have introduced error in histological CVF quantification, as may cause of death. In the current study, hearts remained in vivo until explantation when they were immediately fixed in formalin, minimizing postmortem changes. The interval between CMR and transplantation could have resulted in changes in myocardial collagen content. However in 5 of the 6 patients, the interval was minimal (≤40 days). There was a small improvement in correlation between DynEq-CMR-derived ECV and histological CVF when ECV was calculated using the 15-minute postcontrast T 1 values compared with when the 10-minute postcontrast values were used. As such, the optimal postcontrast time for T 1 acquisition was not ascertained, and it is possible that the correlation may have improved further with later postcontrast T 1 measurements. However, the clinical status of the patients involved, that is, end-stage heart failure, necessitated relatively short scan duration. Finally, an alternative CMR method of quantifying ECV that has been less commonly applied than the methods assessed here, in which contrast agent kinetics are deconvoluted using mathematical modeling, was not investigated. 41 
Conclusions
This study provides comprehensive validation of the DynEq-CMR method for measurement of myocardial ECV. Isolated postcontrast measurement of myocardial T 1 is insufficient for ECV assessment.
